Malgorzata Miakisz

Featured in: Favicon

biomedcentral.com Favicon

onlinelibrary.wiley.com Favicon

arthritis-research.biomedcentral.com

Articles

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

May 17, 2023 | onlinelibrary.wiley.com | Philip Mease |Philip Helliwell |Paula Silwinska-Stanczyk |Malgorzata Miakisz

Study design and treatment This was a phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-treatment-group, efficacy, and safety study conducted across 11 countries in Europe between June 2019 and January 2021.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →